NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

No, we are not angry. We are more patient. There are several points you might forget to mention.

The vetting done by BMY and Merck on NWBO before collaboration on the combo trial guarantees it. The patent monopoly built up by NWBO on dendritic cells guarantees it. The exponential increase in R&D on immunotherapy from BPs guarantees it. The intense competition in the crowd field of pd-1 inhibitors guarantees it. The eagerness of switching to subcutaneous administration for pd-1 inhibitors guarantees it. The hiring frenzy in British manufacturing facility guarantees it. The data on the combo trial from Linda Liau's latest present guarantees it.